Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Announces Target Price $40
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Cuts Target Price to $35
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating
CareDx: Strong Financial Performance and Strategic Positioning Support Buy Rating Amid Positive Long-Term Growth Prospects
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating
CareDx Analyst Ratings
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
CareDx Faces Challenges Amid Disappointing Financial Performance and Overambitious Growth Targets, Warrants Sell Rating by Analyst
Goldman Sachs Maintains CareDx(CDNA.US) With Buy Rating, Raises Target Price to $35
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $40
Buy Rating on CareDx: A Positive Outlook Amidst Legal Resolutions and Growth Potential
BTIG Maintains CareDx(CDNA.US) With Buy Rating, Maintains Target Price $40
Buy Rating Affirmed for CareDx: Leadership Enhancements and Undervalued Stock Present Growth Opportunities
Jefferies Initiates CareDx(CDNA.US) With Sell Rating, Announces Target Price $28
CareDx Initiated at Underweight by Wells Fargo
Wells Fargo Initiates Coverage On CareDx With Underweight Rating, Announces Price Target of $28